ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ACET Adicet Bio Inc

2.33
0.00 (0.00%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 534,078
Bid Price 2.32
Ask Price 2.35
News (1)
Day High 2.395

Low
1.10

52 Week Range

High
7.50

Day Low 2.31
Share Name Share Symbol Market Stock Type
Adicet Bio Inc ACET NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 2.33 18:43:40
Open Price Low Price High Price Close Price Previous Close
2.33 2.31 2.395 2.35 2.33
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
2,719 534,078 US$ 2.35 US$ 1,256,995 - 1.10 - 7.50
Last Trade Type Quantity Price Currency
18:33:53 formt 600 US$ 2.33 USD

Adicet Bio Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
98.42M 43.16M - 24.99M -69.79M -1.62 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Adicet Bio News

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ACET Message Board. Create One! See More Posts on ACET Message Board See More Message Board Posts

Historical ACET Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.142.3952.022.16950,2130.198.88%
1 Month2.382.541.882.211,535,200-0.05-2.10%
3 Months2.003.771.882.701,873,9550.3316.50%
6 Months1.453.771.102.441,090,3860.8860.69%
1 Year5.897.501.102.80882,987-3.56-60.44%
3 Years13.1021.871.108.38636,741-10.77-82.21%
5 Years0.155721.870.13068.22582,3722.171,396.47%

Adicet Bio Description

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

Your Recent History

Delayed Upgrade Clock